Table 1.
Treg adoptive transfer in clinical trials.
| HCT type | Clinical approach | Patients treated | Treg isolation | Treg number/kg | GvHD outcome | |
|---|---|---|---|---|---|---|
| Trzonkowski et al., 2009 [78] | HLA-matched | T: aGvHD and cGvHD | 2 (1 aGvHD and 1 cGvHD) | Magnetic separation FACS sorting In vitro expansion |
cGvHD (1 × 105) aGvHD (2 × 106) |
1 (cGvHD) response |
|
| ||||||
| Brunstein et al., 2011 [75] | Cord blood | P | 23 | Magnetic separation In vitro expansion |
1 × 105–3 × 106 | aGvHD II–IV (43%) aGvHD III-IV (17%) cGvHD (14%) |
|
| ||||||
| Di Ianni et al., 2011 [76] | Haploidentical | P | 28 | Magnetic separation | 2 × 106–4 × 106 | aGvHD (2/26) No reported cGvHD |
|
| ||||||
| Martelli et al., 2014 [77] | Haploidentical | P | 43 | Magnetic separation | 2 × 106 | aGvHD (6/41) cGvHD (1/41) |
|
| ||||||
| Theil et al., 2015 [79] | HLA-matched (4) Cw mismatch (1) |
T: cGvHD | 5 | Magnetic separation In vitro expansion |
Median 2.36 × 106 | Response (2) Stable (3) |
T: treatment; P: prevention.